𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

✍ Scribed by Facendola, G; Locatelli, MC; Pizzocaro, G; Piva, L; Pegoraro, C; Pallavicini, EB; Signaroldi, A; Meregalli, M; Lombardi, F; Beretta, GD

Book ID
109837197
Publisher
Nature Publishing Group
Year
1995
Tongue
English
Weight
891 KB
Volume
72
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sequential treatment of patients with ad
Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon Ξ±2b
✍ S. Pomer; R. Thiele; V. Daniel; R. Weimer; H. LΓΆhrke; V. Schirrmacher; G. Staehl πŸ“‚ Article πŸ“… 1991 πŸ› Springer-Verlag 🌐 English βš– 820 KB

Thirty patients with advanced renal cell carcinoma (RCC), 23 of whom had distant metastases in at least one organ, were entered after nephrectomy into a protocol involving vaccination with Newcastle disease virus (NDV)-modified autologous tumour material, with a subsequent induction week and repetit

Immunotherapy of advanced renal cell can
Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-Ξ±
✍ H. Kirchner; W. Riese; E. Allhoff; H. Poliwoda; J. Atzpodien πŸ“‚ Article πŸ“… 1991 πŸ› Springer-Verlag 🌐 English βš– 450 KB

The combined administration of subcutaneous recombinant human interleukin-2 (rIL-2) and interferon-a (rIFN-~) was studied in a phase II trial on patients with advanced progressive renal cell cancer. Safety, tolerance and clinical response rate of this outpatient treatment protocol were assessed in 2